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Abstract
Centrosomes, each containing a pair of centrioles, organize microtubules in animal cells, particularly
during mitosis. DNA and centrosomes are normally duplicated once prior to cell division to maintain
optimal genome integrity. We report a new role for the Orc1 protein, a subunit of the Origin
Recognition Complex (ORC) that is a key component of the DNA replication licensing machinery
in controlling centriole and centrosome copy number in human cells, independent of its role in DNA
replication. Cyclin A promotes Orc1 localization to centrosomes where Orc1 prevents Cyclin E-
dependent re-duplication of both centrioles and centrosomes in a single cell division cycle. The data
suggest that Orc1 is a regulator of centriole and centrosome re-duplication as well as the initiation
of DNA replication.
The assembly of a bipolar, microtubule spindle during mitosis is essential for accurate
chromosome segregation. In animal cells, spindle formation is organized by centrosomes,
organelles that contain of a pair of centrioles surrounded by pericentriolar material (PCM) that
need to be duplicated exactly once every cell division cycle, in coordination with DNA
replication to maintain genome stability (1). Licensing DNA for replication is a critical
regulatory step involving the Origin Recognition Complex (ORC), the first component for
assembly of a pre-Replicative-Complex (pre-RC) at each origin (2). Accumulated evidence
supports roles for ORC subunits in addition to licensing DNA replication (3). In particular,
human Orc2 subunit localizes to centrosomes and depletion of Orc2 and Orc3 causes
centrosome amplification in mitosis (4).
Several regulators of the DNA licensing machinery have been reported to be involved in the
control of both DNA and centriole duplication (5). Both cyclin E and cyclin A, as well as Cdk2
activity are well known positive regulators of DNA replication and also promote centrosome
duplication (or re-duplication) (6–11). Depletion of the DNA replication licensing inhibitor
Geminin causes re-duplication of both DNA and centrosomes in human cells (12).
In a screen using short interfering RNA (siRNA) for human ORC proteins with roles in
centrosome biology, we found that depletion of the largest human ORC subunit, HsOrc1, leads
to excess centrosomes (fig. S1, Fig. 1A). Orc1 siRNA-treated U2OS cells were analyzed for
centrosome defects by dual-color indirect immunofluorescence (IF) using anti-centrin 2 (stains
centrioles) and anti--tubulin (stains centrosomes) antibodies. 72 hr post siRNA, 39.77 ± 3.5%
of cells transfected with Orc1-1 siRNA and 25.53 ± 0.3% of cells transfected with Orc1-2
5To whom correspondence should be addressed. E-mail: stillman@cshl.edu.
3(present address) Department of Cell and Developmental Biology, 601 S. Goodwin Avenue, University of Illinois at Urbana-Champaign,
IL 61801 USA
4(present address) Clare Hall Laboratories, Cancer Research UK, South Mimms, Herts, EN6 3LD, UK
NIH Public Access
Author Manuscript
Science. Author manuscript; available in PMC 2009 August 6.
Published in final edited form as:













siRNA showed multiple centrosomes and centrioles, in comparison to 2.4 ± 1.2% of control
cells (fig. S1C). In Orc1-1 treated cells 33.29 ± 2.6% of the multiple centrosomes were
separated rather than linked and the re-duplication occurred in different human cell lines (fig.
S1 and S2).
To study the kinetics of centriole and centrosome re-duplication after Orc1 depletion, U2OS
cells were synchronized in mitosis by nocodazole treatment and released into the next cycle.
Centriole and centrosome numbers were assessed 12 hr, 36 hr and 60 hr after nocodazole release
(Fig. 1B, fig. S3). Disorganized disengagement of duplicated centrioles (2Pairs - Dis.) was
observed 12 hr after release when most of the cells were in G1 or early S phase (Fig. 1B, fig
S3; centrin 2). This was followed by an increase in the percentage of cells showing centriole
re-duplication (>2P). The complete centrosome structure, as evidenced by -tubulin staining,
was observed later, mostly 60 hr after release (-tubulin). The very early effect of Orc1 depletion
on centriole disengagement and re-duplication suggests that Orc1 might have a more direct
effect on these processes, whereas complete centrosome formation follows centriole re-
duplication. Similar dynamics of centriole re-duplication after Orc1 depletion were observed
in HeLa cells (fig. S4). It has been proposed that centriole engagement blocks re-duplication
(13). In Orc1 depleted cells, however, the duplicated centrioles were found disengaged and
underwent re-duplication, suggesting that Orc1 may block re-duplication by participating in
processes of centriole engagement of the newly duplicated centrioles.
Different mechanisms for centrosome amplification have already been reported. Apparent
multiple centrosomes can arise by centrosome fragmentation, centriole splitting that occurs
during early mitosis after DNA damage (14) or authentic re-duplication. Analysis of multiple
parameters including DNA content (fig. S1B), cell cycle markers (fig. S5), centriolin staining
of mature centrosomes (fig. S6 and S7) and the numbers of centrioles per PCM (Fig. 1A) all
indicate that Orc1 depletion causes bona fide centriole and centrosome re-duplication in U2OS
cells (see supplemental text).
To address whether over-expression of Orc1 would affect centrosome re-duplication caused
by prolonged S-phase arrest in the presence of hydroxyurea (HU) (9,15), U2OS cells were
transiently transfected with YFP-Orc1WT, YFP-Orc2 or a vector carrying only YFP in the
presence of HU (Fig. 2A and D; fig. S8). Centrosome re-duplication after HU treatment, but
not normal duplication, was substantially inhibited in YFP-Orc1WT cells, whereas YFP or
YFP-Orc2 did not have any effect, suggesting a role for Orc1 as an inhibitor of centrosome re-
duplication.
YFP-Orc1 associated with centrosomes in addition to its nuclear localization in approximately
35% of transfected cells (fig. S9A and Video 1). Furthermore, endogenous Orc1 and other
ORC subunits co-fractionated with purified centrosomes (fig. S9B). Transiently expressed
Orc1 fused to the PACT domain, a conserved motif that targets proteins to centrosomes (16),
resulted in inhibition of centrosome re-duplication in HU-treated U2OS cells (Fig. 2B and D),
suggesting that Orc1 controls centrosome copy number when located at centrosomes.
Centrosome re-duplication was significantly inhibited by the full length and N terminal region
of Orc1 (aa 1 to 500; Orc1WT. Nterm. Flag; Fig. 2C), the latter of which is deficient ORC
assembly (17). Both Orc1 versions also inhibited centrosome re-duplication when expressed
after the application of the HU block, indicating that the inhibition was not caused by a G1
arrest in these cells (fig. S10). Thus Orc1 control of centrosome copy-number is separate from
its DNA replication role, does not require assembly of into ORC, but such assembly may
facilitate a more efficient block.
Orc1 depletion in synchronized U2OS cells did not trigger early responses of DNA damage
checkpoint pathways that are known to affect centriole and centrosome copy number (18,19).
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Activation of Chk1 by phosphorylation on serine 317 was not detected and p27 and the p53
pathways were activated well after centriole amplification was initiated (Fig. 1B, fig. S11).
Several reports have shown that Cyclin E over-expression in mammalian cells is linked to
genome and centrosome abnormalities (20,21) and that centrosome re-duplication requires
Cdk2 activity (7–9,11). Elevated levels of Cyclin E were identified as early as 12hr after release
of synchronized Orc1-depleted U2OS cells in Cyclin A negative cells (Fig. 3A and 3B, also
see fig. S5A and S5B) and continued to increase. We thus hypothesized that Orc1 control of
centriole and centrosome re-duplication involved Cyclin E and Cdk2. The Cdk2 inhibitor
roscovitine suppressed centriole and centrosome re-duplication in Orc1 depleted cells (fig.
S12). In a second experiment, simultaneous depletion of Orc1 and Cyclin E blocked centriole
and centrosome re-duplication, whereas normal duplicated centriole and centrosome numbers
were observed (Fig. 3C, fig. S13A). Cyclin E siRNA did not change the number of cells with
a 4C DNA content after Orc1-1 treatment (fig. S13B), implying that the block of centrosome
over-duplication in Orc1-1 depleted cells by Cyclin E siRNA was not due to a compete G1
arrest. In contrast, Cyclin A siRNA did not abolish centrosome re-duplication in Orc1 depleted
cells (Fig. 3C).
We tested the ability of elevated levels of cyclins to cause centrosome re-duplication in HU
treated cells expressing YFP. Orc1WT (Fig. 4A). Co-expression of Cyclin E with YFP.
Orc1WT blocked YFP. Orc1WT inhibition of HU-induced centrosome re-duplication, whereas
neither Cyclin A nor Cyclin B had any effect (Fig. 4A and B). HU treated cells co-expressing
YFP. Orc1WT with Cyclin A showed a cytoplasmic pool of over-expressed YFP. Orc1WT in
addition to the nuclear localization and an enhancement of YFP-Orc1 located at centrosomes
(Fig. 4B, b–b; the number of YFP-Orc1 positive centrosomes in the presence of Cyclin A
increased six-fold compared to YFP-Orc1 alone). Co-expression of Cyclin E with YFP.
Orc1WT. PACT also eliminated the ability of YFP. Orc1WT. PACT to block centrosome re-
duplication, whereas Cyclin A or Cyclin B had no effect (Fig. 4A and B). Altogether, the results
suggest that Orc1 might directly regulate centriole and centrosome copy number in cells, and
the mechanism involves Cyclin E.
Orc1 co-precipitated with Cyclin E and Cyclin A, as previously shown (22), whereas no
association was observed with Cyclin B (Fig. 4C). Association in a complex with Cyclin E
was stronger than with Cyclin A; however, so far we have not been able to find evidence that
Orc1 binds Cyclin E directly. Nevertheless, purified wild type Orc1 inhibited Cyclin E-Cdk2
and Cyclin A-Cdk2 kinase activity using histone H1 as substrate (fig. S14B).
The Orc1 ‘RXL’ mutant (K235A-L237A, Orc1A-A) impairs the direct interaction with Cyclin
A, but does not affect Cyclin E binding (Fig. 4C; fig. S14A) and cannot block Cyclin A
associated kinase activity (fig. S14B). Although some inhibition was observed, Orc1A-A and
Orc1A-A. Nterm did not block centrosome re-duplication as efficiently as wild type Orc1,
suggesting that Orc1-Cyclin A interaction is required for optimal centrosome copy number
control (Fig. 4D). Orc1A-A. PACT blocked centrosome re-duplication to the same extent as
Orc1WT. PACT (Fig. 4E). Since Cyclin A function has been previously linked to the
cytoplasmic localization of Orc1 (23), possibly Orc1A-A and Orc1A-A. Nterm mutants were
not exported efficiently to centrosomes to block HU-induced re-duplication, whereas
Orc1A-A. PACT was directly targeted to centrosomes. Accordingly, Cyclin A stimulation of
Orc1 association with centrosomes was significantly reduced when co-expressed with the
‘RXL’ Orc1A-A mutant . Altogether, the data indicates that both Cyclin E and Cyclin A play
a role in Orc1 mediated control of centrosome numbers.
ORC in human cells is dynamically assembled and disassembled during the cell cycle and
participates in many aspects of chromosome duplication and segregation, including functions
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at kinetochores, centromeres and heterochromatin (3). Orc2 is localized to centrosomes, but
its depletion affects centrosome copy number in mitosis in addition to controlling DNA
replication, centromere activity and chromosome structure (4). In contrast, Orc1 controls
Cyclin E-dependent centrosome copy number by directly preventing re-duplication of
centrioles immediately after centrioles duplicate upon commitment to cell division. Without
Orc1, duplicated centrioles are disengaged and extensive Cyclin E-dependent centriole re-
duplication occurs. Note that in the absence of Orc1 and Cyclin E, centrioles duplicate, but
they do not re-duplicate, suggesting that such centriole duplication is Cyclin A dependent,
consistent with previous studies (24). But in the absence of Cyclin E and Orc1, centrosome re-
duplication does not occur. Similarly, Cyclin E, but not Cyclin A over-rides the Orc1 inhibition
of centrosome-re-duplication.
Cyclin E is required for centrosome duplication and re-duplication and co-precipitates with
Orc1 (7,11,25–27). We have not been able to detect direct binding between Cyclin E and Orc1,
suggesting that a mediator protein may facilitate the binding. The mediator may be another
DNA replication protein implicated in centrosome biology (12,28). Furthermore, depletion of
Orc1 increases Cyclin E protein levels in cells that may contribute to centriole re-duplication.
Both proteins are degraded by SCF, which localizes to centrosomes and has also been
implicated in control of centrosome duplication (29,30).
There is a short time during the cell division cycle after centrioles have duplicated when Cyclin
E is still present in cells (late G1 and early S phase). During this time, if Cyclin E activity is
not checked, centriole re-duplication might occur. We suggest that a mechanism involving
Cyclin A-dependent localization of Orc1 to centrosomes that prevents Cyclin E-dependent
centriole re-duplication during this time window (fig. S15). In this manner, Orc1 plays a dual
role in coordinating DNA replication and centrosome copy number.
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Fig. 1. Orc1 depletion causes centriole and centrosome re-duplication
(A) Human U2OS cells treated for 72 hours with Orc1-1 siRNA duplex were co-
immunostained for centrioles with anti-centrin 2 (green, a to e) and centrosomes with anti--
tubulin (red, a to e) antibodies. Insets are higher magnification. DNA was stained with DAPI
(blue) and merged images are shown in a to e. Scale bar, 10 m. (B) Quantification of centrosome
and centriole numbers by -tubulin (upper panel) and centrin 2 (Bottom panel) immunostaining,
respectively. Cells were harvested at 12, 36 or 60 hours after nocodazole release. Error bars
represent one standard error.
1C, one centrosome; 2C(L), two centrosomes linked; 2C(S), two centrosomes separated; >=3C
(L), three or more centrosomes linked; >=3C(S), three or more centrosomes separated. 1Pair,
one centriole pair; 2 Pairs (L), two centriole pairs linked; 2 Pairs (S), two centriole pairs
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separated; 2 Pairs (Dis.), two centriole pairs with disorganized disengaged; >=2 Pairs, more
than two centriole pairs.
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Fig. 2. Over-expression of Orc1 blocks centrosome re-duplication
U2OS asynchronous cells were transfected (or not, UNT) with the indicated constructs (see
text) and treated with 16mM hydroxyurea (+ or HU). Cells were harvested at 68 hours after
HU-treatment. Centrosome numbers were scored by -tubulin immunostaining in YFP or Flag
positive cells. (A–C) Quantification of multiple centrosomes in HU-arrested cells. (D) Cells
were immunostained for centrosomes with anti -tubulin (red, a to i); YFP expression was
immunostained with anti-GFP in (A) (green, a to d) or visualized directly in (B) (e, f); and Flag
expression was immunostained with anti-Flag in (C) (g to i). DNA was stained with DAPI
(blue) and merged images are shown in a to i. Scale bar, 10 m. Insets are higher magnification.
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Fig. 3. Orc1 depletion causes Cdk2 and Cyclin E-dependent centriole and centrosome re-
duplication
(A) and (B) Nocodazole arrested U2OS cells were transfected with control (GL3) or Orc1-1
siRNA, then released into the next cycle and re-transfected with the same siRNA duplexes.
(A) Immunoblot of whole-cell extract of cells harvested at the indicated time points. Orc1,
Cyclin E, Cyclin A and -tubulin levels were assessed by immunoblotting with specific
antibodies. Cyclin E*, a longer exposure. (B) Cells were harvested at 12 hours after nocodazole
release and co-immunostained with anti-Cyclin E (green) and anti-Cyclin A (red). DNA was
stained with DAPI (blue) and merged images are shown in a and b. Scale bar, 30 m. (C)
Quantification of centrosome and centriole numbers by -tubulin and centrin 2 immunostaining,
respectively, of asynchronous U2OS cells transfected with the indicated siRNAs. Cells were
analyzed 72 hours after the first transfection. Error bars represent one standard error.
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Fig. 4. Cyclin E suppresses Orc1 inhibition of centrosome re-duplication in S-phase-arrested cells
In A, B, C and D: U2OS asynchronous cells were transfected with the indicated constructs (see
text) and treated with 16mM hydroxyurea (+HU). Untransfected cells were treated or not with
HU (UNT +HU and UNT HU, respectively). Cells were harvested at 68 hours after transfection
and HU-treatment. (A) Quantification of multiple centrosomes in transfected HU-arrested
cells. Centrosome numbers were scored by -tubulin immunostaining in YFP positive cells.
Error bars represent one standard error. (B) Transfected, HU-treated cells were immunostained
for centrosomes with anti -tubulin (red, a to d) and YFP expression was visualized directly
(green, a to d). DNA was stained with DAPI (blue) and merged images are shown in a to d.
Scale bar, 10 m. (C) Immunoprecipitation with anti-Flag antibody from whole-cell extract from
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HEK293 cells transiently co-expressing the indicated constructs and immunoblotting with the
indicated antibodies. Vector, full-length Orc1WT. Flag (wild type) or full-length Orc1A-A. Flag
(mutant) were transiently transfected alone (); or with either T7-Cyclin E, T7-Cyclin A or T7-
Cyclin Right panel: 10% of the immunoprecipitates. (D) and (E) Quantification of multiple
centrosomes in transfected HU-arrested cells. Centrosome numbers were scored by -tubulin
immunostaining in Flag positive cells in (D), and by -tubulin immunostaining in YFP positive
cells directly visualized in (E). Error bars represent one standard error.
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